High Rates of Late HIV Diagnosis Among People Who Inject Drugs Compared to Men Who Have Sex with Men and Heterosexual Men and Women in Australia

2012 ◽  
Vol 17 (1) ◽  
pp. 235-241 ◽  
Author(s):  
Handan Wand ◽  
Rebecca Guy ◽  
Matthew Law ◽  
David P. Wilson ◽  
Lisa Maher
2020 ◽  
pp. 095646242094756
Author(s):  
Sabina O Nduaguba ◽  
Kentya H Ford ◽  
James P Wilson ◽  
Kenneth A Lawson ◽  
Robert L Cook

We aimed to identify subgroups within age, racial/ethnic, and transmission categories that drive increased risk for late HIV diagnosis (LHD). A 1996–2013 retrospective study of HIV-diagnosed individuals (N = 77,844) was conducted. The proportion of individuals with LHD (AIDS diagnosis within 365 days of HIV diagnosis) was determined, stratified by age, race/ethnicity, and transmission category. Logistic regression with interaction terms was used to identify groups/subgroups at risk for LHD during 1996–2001, 2002–2007, and 2008–2013. Respectively, 78%, 27%, 38%, and 31% were male, White, Black, and Hispanic. Overall, 39% had LHD with a 6.7% reduction for each year increase (OR = 0.93, 95% CI = 0.93–0.94, p < 0.01). Older age was significantly associated with increased odds of LHD (OR range = 1.90–4.55). Compared to their White counterparts, all Hispanic transmission categories (OR range = 1.31–2.58) and only Black female heterosexuals and men who have sex with men (MSM) (OR range = 1.14–1.33) had significantly higher odds of LHD during 1996–2001 and/or 2002–2007. Significance was limited to Hispanic MSM (all age categories), MSM/IDUs (30–59 years), and heterosexuals (18–29 years) and Black MSM (30–39 years) during 2008–2013. Older individuals and Hispanics (driven by MSM) are at increased risk for LHD. HIV testing interventions directed at seniors and Hispanic MSM can further reduce rates of LHD.


2014 ◽  
Vol 67 (4) ◽  
pp. 438-445 ◽  
Author(s):  
Sharon B. Mannheimer ◽  
Lei Wang ◽  
Leo Wilton ◽  
Hong Van Tieu ◽  
Carlos del Rio ◽  
...  

2009 ◽  
Vol 13 (6) ◽  
pp. 1129-1142 ◽  
Author(s):  
Carol Golin ◽  
Gary Marks ◽  
Julie Wright ◽  
Mary Gerkovich ◽  
Hsiao-Chuan Tien ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0172664 ◽  
Author(s):  
Haiyang Hu ◽  
Hongjing Yan ◽  
Xiaoyan Liu ◽  
Xiaoqin Xu ◽  
Jinshui Xu ◽  
...  

Sexual Health ◽  
2012 ◽  
Vol 9 (6) ◽  
pp. 501 ◽  
Author(s):  
Christopher K. Fairley ◽  
Julia M. L. Brotherton ◽  
Richard Hillman ◽  
Andrew E. Grulich

This editorial describes the contents of this special issue of Sexual Health devoted to anal cancer. The aim of the issue is to provide readers with information to assist them in making decisions about what to do about detecting anal cancer early in men who have sex with men with HIV. Should they be advocating screening? It discusses the epidemiology of HPV infection, anal intraepithelial neoplasia, and anal cancer in MSM, heterosexual men and women; anal cancer screening and treatment of anal cancer. And most importantly, what should be done about vaccinating boys with the HPV vaccine.


2012 ◽  
Vol 60 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Sara Nelson Glick ◽  
Martina Morris ◽  
Betsy Foxman ◽  
Sevgi O. Aral ◽  
Lisa E. Manhart ◽  
...  

2017 ◽  
Vol 11 (1) ◽  
pp. 35-45
Author(s):  
Carmen Rodríguez Cerdeira ◽  
Sánchez Blanco E ◽  
Sánchez Blanco B ◽  
Carnero Gregorio M

Background:Pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) as a method of HIV prevention is not without controversy, and there has been concern that it may lead its users to think that they no longer need other preventive measures such as condoms. Thus, healthcare providers are convinced that PrEP decreases condom use and increases sexually transmitted infections (STIs). This treatment has been studied in men who have sex with men, men and women in heterosexual HIV-discordant couples, and heterosexual men and women.Objective:The objective of this study was to review the current state of evidence on the association of PrEP with condom use, the incidence of STIs, and the change in sexual behaviours in populations with risky practices.Materials and Methods:PubMed (National Center for Biotechnology Information, Bethesda, MD, USA), Science Direct (Elsevier Ltd., Oxford, UK), and Google Scholar (Google Inc., Mountain View, CA, USA) search engines were used during the study. We used the terms HIV, PrEP, sexually transmitted infections (STIs), MSM, condom, heterosexual men / women to search the databases.Results:Here, we present evidence that daily oral treatment is safe and effective in these populations studied, especially when medication adherence is high. STI testing should include extra-genital testing regardless of PrEP use to prevent health deficits and onward transmission.Conclusion:Despite this safety and efficacy, we strongly advise that patients continue to use condoms as a prophylactic measure against other sexually transmitted diseases. This update addresses the benefits and precautions that must be taken when establishing PrEP treatment, focusing mainly on family doctorswho are best positioned to provide follow-up and advice to patients and their relatives.


Sign in / Sign up

Export Citation Format

Share Document